Clinical impact of non-high density lipoprotein-cholesterol and apolipoprotein B on clinical outcomes in metabolic syndrome patients with acute myocardial infarction undergoing percutaneous coronary intervention

Korean Circulation Journal

Volumn 42, Issue 5, 2012, Pages 319-328

  Ahmed, Khurshid ^a,b   Jeong, Myung Ho ^a   Chakraborty, Rabin ^b   Hong, Young Joon ^a   Oh, Mi Sook ^a   Cho, Kyung Hoon ^a   Kim, Min Chol ^a   Hachinohe, Daisuke ^a   Hwang, Seung Hwan ^a   Lee, Min Goo ^a   Sim, Doo Sun ^a   Park, Keun Ho ^a   Kim, Ju Han ^a   Ahn, Youngkeun ^a   Kang, Jung Chaee ^a  

^a Chonnam National University Medical School   (South Korea)

^b Apollo Gleneagles Hospital   (India)

Author keywords

Apolipoproteins B; Cholesterol; Metabolic syndrome; Myocardial infarction

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME;

EID: 84862521009     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2012.42.5.319     Document Type: Article

References (27)

1. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-22.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
3. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C; ACCESS Study Group. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001;88:265-9.
4. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
5. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9.
6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
7. Lee KH, Jeong MH, Ahn YK, et al. Sex differences of the clinical characteristics and early management in the Korea acute myocardial infarction registry. Korean Circ J 2007;37:64-71.
8. Sim DS, Kim JH, Jeong MH. Differences in clinical outcomes between patients with ST-elevation versus non-ST-elevation acute myocardial infarction in Korea. Korean Circ J 2009;39:297-303.
9. Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J 2002;144:981-6.
10. Kini AS. Coronary angiography, lesion classification and severity assessment. Cardiol Clin 2006;24:153-62.
11. Manginas A, Gatzov P, Chasikidis C, Voudris V, Pavlides G, Cokkinos DV. Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method. Am J Cardiol 1999;83:1562-5.
12. Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation 2003;108:1552-3.
13. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
14. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003;108:1546-51.
15. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-40.
16. Wang TY, Newby LK, Chen AY, et al. Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. Clin Cardiol 2009;32:E22-8.
17. Cho KH, Jeong MH, Ahn Y, et al. Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox). Am J Cardiol 2010;106:1061-8.
18. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:578-84.
19. Gurm HS, Brennan DM, Booth J, Tcheng JE, Lincoff AM, Topol EJ. Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am J Cardiol 2002;90:42-5.
20. Mehta L, Devlin W, McCullough PA, et al. Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction. Am J Cardiol 2007;99:906-10.
21. Prasad A, Stone GW, Aymong E, et al. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. Am Heart J 2004;147:669-75.
22. Tespili M, Guagliumi G, Valsecchi O, et al. In-hospital clinical outcome in elderly patients with acute myocardial infarction treated with primary angioplasty. Ital Heart J 2003;4:193-8.
23. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005;112:3375-83.
24. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Després JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003;91:1173-7.
25. Sattar N, Williams K, Sniderman AD, D'Agostino R Jr, Haffner SM. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 2004;110:2687-93.
26. Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is. Circulation 2005;112:3366-7.
27. Han JH, Park HS, Kim JA, Kim SM. Apolipoprotein B is a better marker than non-HDL-cholesterol for the metabolic syndrome in Koreans. Atherosclerosis 2008;197:333-8.